• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Bioactive Products
    Cardioprotective Compound Library
    A unique collection of 81 Cardioprotective natural compounds for high throughput screening (HTS) and high content screening (HCS).
    Catalog No: Bb1313 Cardioprotective Compound Library
    Screening Details
    Size: 1mg/well * 81 Compounds
    2mg/well * 81 Compounds
    Catalog No. Information
    CFN99208 Squalene

    1. Squalene can significantly suppress colonic aberrant crypt foci (ACF) formation and crypt multiplicity strengthens the hypothesis that squalene possesses chemopreventive activity against colon carcinogenesis.
    2. Squalene is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and has been proposed to inhibit the farnesylation of ras oncoproteins, it can effectively inhibit NNK-induced lung tumorigenesis.
    3. Squalene has cardioprotective effect, it exerts an antioxidant effect against isoproterenol- induced myocardial infarction by blocking the induction of lipid peroxidation, suggests that its cardioprotective effect may be ascribable to its antioxidant property and membrane stabilizing action.
    4. Squalene may be efficacious as a cytoprotectant in cyclophosphamide-induced toxicities.
    CFN99276 DL-Syringaresinol

    1. (+)-Syringaresinol shows inhibitory activity of Helicobacter pylori motility with the IC50 value is 50 microg/ml.
    2. (-)-Syringaresinol has been reported to potently inhibit the proliferation of human promyelocytic HL-60 cells through G 1 arrest and induction of apoptosis, suggests that it may be a potential chemotherapeutic agent for the treatment of cancer.
    3. Syringaresinol induces vasorelaxation by enhancing NO production in endothelial cells via two distinct mechanisms, phosphatidylinositol 3-kinase/Akt- and (PLC)/Ca2+/CaMKKβ -dependent eNOS phosphorylation and Ca(2+)-dependent eNOS dimerization.
    4. Syringaresinol can protect against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1α in a FOXO3-dependent mechanism.
    CFN99112 Scutellarin

    1. Scutellarin attenuates H2O2-induced cytotoxicity, intracellular accumulation of ROS and Ca2+, lipid peroxidation, and loss of MMP and DNA, which may represent the cellular mechanisms for its neuroprotective action.
    2. Long-term administration of scutellarin improved the cardiac function of MI rats by inhibiting interstitial fibrosis, and the mechanisms may involve the suppression of pro-fibrotic cytokine TGFβ1 expression and inhibition of p38 MAPK and ERK1/2 phosphorylation.
    3. Scutellarin has neuroprotection, the mechanism mediated by inhibition of microglial inflammatory activation.
    4. Scutellarin has protective effects for cerebral injury through regulating the expression of NOS isoforms and angiogenic molecules.
    CFN99131 8-Gingerol

    1. 8-Gingerol is one of the principal components of ginger, which is widely used in China and elsewhere as a food, spice and herb, shows immunosuppressive activity on the immune responses to ovalbumin (OVA) in mice, 8-gingerol suppressed lipopolysaccharide (LPS) and concanavalin A (ConA)-stimulated splenocyte proliferation in vitro.
    2. 8-Gingerol suppresses cellular tyrosinase activity and decrease melanin content, inhibits the expression of MC1R, MITF, tyrosinase, TRP1 and TRP2, decreases intracellular RS and ROS levels in B16F10 and B16F1 cells, inhibits melanogenesis by down-regulation of MAPK, PKA signaling pathway; it could be used as an effective skin-whitening agent.
    3. 8-Gingerol has inhibition of T lymphocyte proliferation and cytokine synthesis.
    4. 8-Gingerol has anti-oxidant and anti-inflammatory activities.
    CFN99161 Salvianolic acid A

    1. Salvianolic acid A has protection against cerebral lesion, defense from oxidative damage and improvement of remembrance; it also has antithrombotic effect, antiplatelet action and can modulate hemorheology without affecting coagulation system, the mechanisms underlying such activities may involve the induction of cAMP.
    2. Salvianolic acid A possesses antioxidant activity, also has a significant protective effect against isoproterenol-induced myocardial infarction; it activates the Nrf2/HO-1 axis in RPE cells and protects against oxidative stress via activation of Akt/mTORC1 signaling.
    3. Salvianolic acid A (oral) can significantly improve glucose metabolism and inhibit oxidative injury as well as protect against impaired vascular responsiveness in STZ-induced diabetic rats.
    4. Salvianolic acid A has protection on oxidative stress and liver injury induced by carbon tetrachloride in rats, which may mainly be related to its antioxidative effect.
    5. Salvianolic acid A inhibits platelet activation via the inhibition of PI3K, and attenuates arterial thrombus formation in vivo, suggests that it may be developed as a novel therapeutic agent for the prevention of thrombotic disorders.
    6. Salvianolic acid A is a novel matrix metalloproteinase-9 inhibitor, can prevents cardiac remodeling in spontaneously hypertensive rats.
    7. Salvianolic acid A inhibits PDGF-BB-activated HSC proliferation, partially through apoptosis induction, it exerts no direct cytotoxicity on primary hepatocytes and HSC-T6 cells under experimental concentrations.